NCT05634551Completed
Perceptions on Expected Outcomes of Immunotherapy in Advanced Cancer Patients With Poor Performance Status
Source: ClinicalTrials.gov · Last updated 6 Aug 2024
Brief summary (registry, in English)
To better understand your feelings and expectations about immunotherapy
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 15 (actual)
- First submitted
- 22 Nov 2022
- Start date
- 9 Feb 2023
- Primary completion date
- 2 Aug 2024
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Lung cancer
- NCT number
- NCT05634551
What you commit to
- Study type: Observational
- Participants enrolled: 15
- From 9 Feb 2023 to the primary completion date, 2 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Treatment for curative intent
- Presence of Delirium (as determined by score \>13 on MDAS 46, appendix A)
Who the study is looking for
- Patients being considered for or within 2 months of starting immunotherapy for advanced cancer
- Patient ≥18 years of age
- ECOG ≥2
- Cognitively able to understand consent and complete questionnaire as determined by the interviewer at the time of study enrollment
- English speaking
- Willing to participate in the study and sign informed consent
- The study will include medical oncologists that treat advanced cancers
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| M D Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.